Neurobehavioral Treatment Discovery Team

Publications

Schmitt, LM; Smith, EG; Pedapati, EV; Horn, PS; Will, M; Lamy, M; Barber, L; Trebley, J; Meyer, K; Heiman, M; West, KH J; Hughes, P; Ahuja, S; Erickson, CA. Results of a phase Ib study of SB-121, an investigational probiotic formulation, a randomized controlled trial in participants with autism spectrum disorder. Scientific Reports. 2023; 13:5192.

Straub, D; Schmitt, LM; Boggs, AE; Horn, PS; Dominick, KC; Gross, C; Erickson, CA. A sensitive and reproducible qRT-PCR assay detects physiological relevant trace levels of FMR1 mRNA in individuals with Fragile X syndrome. Scientific Reports. 2023; 13:3808.

Jones, A; Kang, S; Shaffer, RC; Erickson, CA; Schmitt, LM. Behavioral inflexibility in fragile X syndrome: Accounts from caregivers and self-advocates. Frontiers in Psychology. 2023; 14:1118652.

Norris, JE; Schmitt, LM; De Stefano, LA; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. Neuropsychiatric feature-based subgrouping reveals neural sensory processing spectrum in female FMR1 premutation carriers: A pilot study. Frontiers in Integrative Neuroscience. 2023; 17:898215.

Beversdorf, DQ; Anagnostou, E; Hardan, A; Wang, P; Erickson, CA; Frazier, TW; Veenstra-VanderWeele, J. Editorial: Precision medicine approaches for heterogeneous conditions such as autism spectrum disorders (The need for a biomarker exploration phase in clinical trials - Phase 2m). Frontiers in Psychiatry. 2023; 13:1079006.

Schmitt, LM; Arzuaga, AL; Dapore, A; Duncan, J; Patel, M; Larson, JR; Erickson, CA; Sweeney, JA; Ragozzino, ME. Parallel learning and cognitive flexibility impairments between Fmr1 knockout mice and individuals with fragile X syndrome. Frontiers in Behavioral Neuroscience. 2023; 16:1074682.

Schmitt, LM; Li, J; Liu, R; Horn, PS; Sweeney, JA; Erickson, CA; Pedapati, EV. Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Molecular Autism. 2022; 13:47.

Norris, JE; Destefano, LA; Schmitt, LM; Pedapati, EV; Erickson, CA; Sweeney, JA; Ethridge, LE. Hemispheric Utilization of Alpha Oscillatory Dynamics as a Unique Biomarker of Neural Compensation in Females with Fragile X Syndrome. ACS Chemical Neuroscience. 2022; 13:3389-3402.

Berry-Kravis, E; Hagerman, R; Budimirovic, D; Erickson, C; Heussler, H; Tartaglia, N; Cohen, J; Tassone, F; Dobbins, T; Merikle, E; Sebree, T; Tich, N; Palumbo, JM; O’Quinn, S. A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX). Journal of Neurodevelopmental Disorders. 2022; 14:56.

Boggs, AE; Schmitt, LM; McLane, RD; Adayev, T; LaFauci, G; Horn, PS; Dominick, KC; Gross, C; Erickson, CA. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Scientific Reports. 2022; 12:5617.

Jonak, CR; Pedapati, EV; Schmitt, LM; Assad, SA; Sandhu, MS; DeStefano, L; Ethridge, L; Razak, KA; Sweeney, JA; Binder, DK; Erickson, CA. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2022; 14:52.

Pedapati, E; Ethridge, L; Sweeney, J; Miyakoshi, M; Schmitt, L; Liu, R; Wu, S; Gilbert, D; Horn, P; Erickson, CA. THALAMOCORTICAL DYSRHYTHMIA AS A UNIFYING MODEL OF NEUROPSYCHIATRIC AND NEUROSENSORY DYSFUNCTION IN FRAGILE X SYNDROME. Journal of the American Academy of Child and Adolescent Psychiatry. 2022; 61:s275-s276.

Lozano, R; Thompson, T; Dixon-Weber, J; Erickson, CA; Berry-Kravis, E; Williams, S; Smith, E; Frazier, JA; Rosselot, H; Farmer, C; Hessl, D. Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives. Genes. 2022; 13:1660.

Schmitt, LM; Sweeney, JA; Erickson, CA; Shaffer, R. Brief Report: Feasibility of the Probabilistic Reversal Learning Task as an Outcome Measure in an Intervention Trial for Individuals with Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2022; 52:4191-4199.

Yurkovic, JR; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Kennedy, DP; Yu, C. Using head-mounted eye tracking to examine visual and manual exploration during naturalistic toy play in children with and without autism spectrum disorder. Scientific Reports. 2021; 11:3578.

Henneberry, E; Lamy, M; Dominick, KC; Erickson, CA. Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder. Journal of Autism and Developmental Disorders. 2021; 51:4370-4394.

Smith, EG; Pedapati, EV; Liu, R; Schmitt, LM; Dominick, KC; Shaffer, RC; Sweeney, JA; Erickson, CA. Sex differences in resting EEG power in Fragile X Syndrome. Journal of Psychiatric Research. 2021; 138:89-95.

Schaefer, TL; Ashworth, AA; Tiwari, D; Tomasek, MP; Parkins, EV; White, AR; Snider, A; Davenport, MH; Grainger, LM; Becker, RA; Gibson, JR; Huber, KM; Gross, C; Erickson, CA. GABAA Alpha 2,3 Modulation Improves Select Phenotypes in a Mouse Model of Fragile X Syndrome. Frontiers in Psychiatry. 2021; 12:678090.

Wink, LK; Reisinger, DL; Horn, P; Shaffer, RC; O'Brien, K; Schmitt, L; Dominick, KR; Pedapati, EV; Erickson, CA. Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study. Journal of Autism and Developmental Disorders. 2021; 51:1392-1399.

Miyakoshi, M; Schmitt, LM; Erickson, CA; Sweeney, JA; Pedapati, EV. Can We Push the "Quasi-Perfect Artifact Rejection " Even Closer to Perfection?. Frontiers in Neuroinformatics. 2021; 14:597079.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Mesoridazine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Thioridazine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Shillington, A; Lamy, M; Vawter-Lee, M; Erickson, C; Saal, H; Comoletti, D; Abell, K. Case Report: Is Catatonia a Clinical Feature of the Natural Progression of NLGN2-Related Neurodevelopmental Disorder?. Journal of Autism and Developmental Disorders. 2021; 51:371-376.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Quetiapine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Alprazolam. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Erickson, CA; Wink, L; McDougle, CJ. Chlorpromazine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Antidepressant Medications. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Doyle, CA; Wink, L; Erickson, CA; McDougle, CJ. Clomipramine. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Abnormal Involuntary Movement Scale. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Sertraline. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Serotonin Syndrome. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Thiothixene. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Aripiprazole. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Atypical Antipsychotics. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Nortriptyline. Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Early, M; Wink, L; Erickson, CA; McDougle, CJ. Serotonin Reuptake Inhibitors (SRIs). Encyclopedia of Autism Spectrum Disorders. : Springer Nature; Springer Nature; 2021.

Wang, T; Hoekzema, K; Vecchio, D; Wu, H; Sulovari, A; Coe, BP; Gillentine, MA; Wilfert, AB; Perez-Jurado, LA; Kvarnung, M; Zhou, X; Turner, TN; Bahl, E; Thomas, TR. Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders. Nature Communications. 2020; 11:4932.

Razak, KA; Dominick, KC; Erickson, CA. Developmental studies in fragile X syndrome. Journal of Neurodevelopmental Disorders. 2020; 12:13.

Aman, MG; Norris, M; Kaat, AJ; Andrews, H; Choo, T; Chen, C; Wheeler, A; Bann, C; Erickson, C. Factor Structure of the Aberrant Behavior Checklist in Individuals with Fragile X Syndrome: Clarifications and Future Guidance. Journal of Child and Adolescent Psychopharmacology. 2020; 30:512-521.

Lamy, M; Pedapati, EV; Dominick, KL; Wink, LK; Erickson, CA. Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents. Pediatric Drugs. 2020; 22:473-483.

Berry-Kravis, E; Horrigan, JP; Tartaglia, N; Hagerman, R; Kolevzon, A; Erickson, CA; Hatti, S; Snape, M; Yaroshinsky, A; Stoms, G; Glass, L; Jones, NE; Investigators, F. A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Fragile X Syndrome. Pediatric Neurology. 2020; 110:30-41.

Reisinger, DL; Shaffer, RC; Tartaglia, N; Berry-Kravis, E; Erickson, CA. Delineating Repetitive Behavior Profiles across the Lifespan in Fragile X Syndrome. Brain Sciences. 2020; 10:E239.

Coffman, MC; Shaffer, RC; Schmitt, LM; Dominick, KC; Pedapati, E; Wang, A; Berry-Kravis, E; Tartaglia, N; Erickson, CA. Examination of Correlates to Health-Related Quality of Life in Individuals with Fragile X Syndrome. Brain Sciences. 2020; 10:E213.

Hoffmann, A; Wang, A; Berger, N; Cordeiro, L; Shaffer, R; Tartaglia, N; Erickson, C; Berry-Kravis, E. Language across the Lifespan in Fragile X Syndrome: Characteristics and Considerations for Assessment. Brain Sciences. 2020; 10:E212.

Fitzpatrick, SE; Schmitt, LM; Adams, R; Pedapati, EV; Wink, LK; Shaffer, RC; Sage, J; Weber, JD; Dominick, KC; Erickson, CA. Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome. Journal of Autism and Developmental Disorders. 2020; 50:1056-1063.

Reisinger, DL; Shaffer, RC; Horn, PS; Hong, MP; Pedapati, EV; Dominick, KC; Erickson, CA. Atypical Social Attention and Emotional Face Processing in Autism Spectrum Disorder: Insights From Face Scanning and Pupillometry. Frontiers in Integrative Neuroscience. 2020; 13:76.

Shaffer, RC; Schmitt, L; Thurman, AJ; Abbeduto, L; Hong, M; Pedapati, E; Dominick, K; Sweeney, J; Erickson, C. The Relationship between Expressive Language Sampling and Clinical Measures in Fragile X Syndrome and Typical Development. Brain Sciences. 2020; 10:E66.

Schmitt, LM; Wang, J; Pedapati, EV; Thurman, AJ; Abbeduto, L; Erickson, CA; Sweeney, JA. A neurophysiological model of speech production deficits in fragile X syndrome. Brain Communications. 2020; 2:fcz042.

Yurkovic, JR; Lisandrelli, G; Shaffer, RC; Dominick, KC; Pedapati, EV; Erickson, CA; Kennedy, DP; Yu, C. (2020) Examining Sustained Attention in Child-Parent Interaction: A Comparative Study of Typically Developing Children and Children with Autism Spectrum Disorder. cognitivesciencesociety.org. 329-335.

Hong, MP; Eckert, EM; Pedapati, EV; Shaffer, RC; Dominick, KC; Wink, LK; Sweeney, JA; Erickson, CA. Differentiating social preference and social anxiety phenotypes in fragile X syndrome using an eye gaze analysis: a pilot study. Journal of Neurodevelopmental Disorders. 2019; 11:1.

Pedapati, EV; Mooney, LN; Wu, SW; Erickson, CA; Sweeney, JA; Shaffer, RC; Horn, PS; Wink, LK; Gilbert, DL. Motor cortex facilitation: a marker of attention deficit hyperactivity disorder co-occurrence in autism spectrum disorder. Translational Psychiatry. 2019; 9:298.

Feliciano, P; Zhou, X; Astrovskaya, I; Turner, TN; Wang, T; Brueggeman, L; Barnard, R; Hsieh, A; Snyder, LG; Muzny, DM; Zaydens, H; Zhang, H; Zhao, H; Consortium, SP A R K. Exome sequencing of 457 autism families recruited online provides evidence for autism risk genes. npj Genomic Medicine. 2019; 4:19.

Eckert, EM; Dominick, KC; Pedapati, EV; Wink, LK; Shaffer, RC; Andrews, H; Choo, T; Chen, C; Kaufmann, WE; Tartaglia, N; Berry-Kravis, EM; Erickson, CA. Pharmacologic Interventions for Irritability, Aggression, Agitation and Self-Injurious Behavior in Fragile X Syndrome: An Initial Cross-Sectional Analysis. Journal of Autism and Developmental Disorders. 2019; 49:4595-4602.

Ethridge, LE; De Stefano, LA; Schmitt, LM; Woodruff, NE; Brown, KL; Tran, M; Wang, J; Pedapati, EV; Erickson, CA; Sweeney, JA. Auditory EEG Biomarkers in Fragile X Syndrome: Clinical Relevance. Frontiers in Integrative Neuroscience. 2019; 13:60.

Gilbertson, KE; Jackson, HL; Dziuban, EJ; Sherman, SL; Berry-Kravis, EM; Erickson, CA; Valdez, R. Preventive care services and health behaviors in children with fragile X syndrome. Disability and Health Journal. 2019; 12:564-573.

McLane, RD; Schmitt, LM; Pedapati, EV; Shaffer, RC; Dominick, KC; Horn, PS; Gross, C; Erickson, CA. Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome. Frontiers in Integrative Neuroscience. 2019; 13:49.

Hong, MP; Erickson, CA. Investigational drugs in early-stage clinical trials for autism spectrum disorder. Expert Opinion on Investigational Drugs. 2019; 28:709-718.